1.
Cytokine-specific autoantibodies shape the gut microbiome in autoimmune polyendocrine syndrome type 1.
Petersen, AØ, Jokinen, M, Plichta, DR, Liebisch, G, Gronwald, W, Dettmer, K, Oefner, PJ, Vlamakis, H, Chung, DC, Ranki, A, et al
The Journal of allergy and clinical immunology. 2021;(3):876-888
-
-
Free full text
-
Abstract
BACKGROUND Gastrointestinal dysfunction is a frequent and disabling manifestation of autoimmune polyendocrine syndrome type 1 (APS-1), a rare monogenic multiorgan autoimmune disease caused by the loss of central AIRE-controlled immune tolerance. OBJECTIVES This study aimed to understand the role of the gut microbiome in APS-1 symptoms and potentially alleviate common gastrointestinal symptoms by probiotic intervention. METHODS This study characterized the fecal microbiomes of 28 patients with APS-1 and searched for associations with gastrointestinal symptoms, circulating anti-cytokine autoantibodies, and tryptophan-related metabolites. Additionally, daily doses of the probiotic Lactobacillus rhamnosus GG were administered for 3 months. RESULTS Of 581 metagenomic operational taxonomic units (mOTUs) characterized in total, 14 were significantly associated with patients with APS-1 compared with healthy controls, with 6 mOTUs depleted and 8 enriched in patients with APS-1. Four overabundant mOTUs were significantly associated with severity of constipation. Phylogenetically conserved microbial associations with autoantibodies against cytokines were observed. After the 3-month intervention with the probiotic L rhamnosus GG, a subset of gastrointestinal symptoms were alleviated. L rhamnosus GG abundance was increased postintervention and corresponded with decreased abundances of Alistipes onderdonkii and Collinsella aerofaciens, 2 species positively associated with severity of diarrhea in patients with APS-1. CONCLUSIONS The APS-1 microbiome correlates with several APS-1 symptoms, some of which are alleviated after a 3-month L rhamnosus GG intervention. Autoantibodies against cytokines appear to shape the gut microbiome by positively correlating with a taxonomically consistent group of bacteria.
2.
[Efficacy of probiotic bactisporin in therapy of intrahospital urinary infection].
Pushkarev, AM
Urologiia (Moscow, Russia : 1999). 2005;(4):48-53
Abstract
We studied efficacy of bactisporin (probiotic based on aerobic spore-forming culture Bacillus subtilis, strain 3H) in combined treatment of intrahospital urinary infection (IUI) in 36 patients with infravesical obstruction. These patients developed postoperative complications due to IUI caused by antibiotic-resistant hospital flora. The control group consisted of 35 patients matched by age and disease given conventional postoperative etiotropic therapy. Bacterial translocation enables bactisporin to enter blood through gastric mucosa. Blood flow delivered the drug to the inflammation focus. Bactisporin can also directly affect IUI pathogen if bacterial suspension is introduced into the cavity. Bacteriological efficacy of the etiotropic scheme including bactisporin against Proteus spp., Ps aeruginosa, Enterobacter spp., Klebsiella spp. made up 72.7-92%. Bactisporin shortened the time of clinical normalization as well as normalization of absolute count of T- and B-lymphocytes, phagocyting leukocytes and immunoglobulin G. Thus, probiotic bactisporin is effective against antibiotic-resistant agents of IUI. It also stimulates immunity promoting clinicoimmunological remission.
3.
Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes.
Gill, HS, Rutherfurd, KJ, Cross, ML
Journal of clinical immunology. 2001;(4):264-71
Abstract
Many elderly subjects are at increased risk of infectious and noninfectious diseases due to an age-related decline in lymphoid cell activity (immunosenescence). Noninvasive means of enhancing cellular immunity are therefore desirable in the elderly. Previous reports have suggested that dietary supplementation could represent an effective means of enhancing the activity of circulating natural killer (NK) cells in the elderly. In the present study, we have conducted a pre-post intervention trial to determine the impact of dietary supplementation with probiotic lactic acid bacteria (LAB) on peripheral blood NK cell activity in healthy elderly subjects. Twenty-seven volunteers consumed low-fat/low-lactose milk supplemented with known immunostimulatory LAB strains (Lactobacillus rhamnosus HN001 or Bifidobacterium lactis HN019) for a period of 3 weeks. A dietary run-in of milk alone was shown to have no significant effect on NK cells. In contrast, the proportion of CD56-positive lymphocytes in peripheral circulation was higher following consumption of either LAB strain, and ex vivo PBMC tumoricidal activity against K562 cells was also increased. Supplementation with HN001 or HN019 increased tumoricidal activity by an average of 101 and 62%, respectively; these increases were significantly correlated with age, with subjects older than 70 years experiencing significantly greater improvements than those under 70 years. These results demonstrate that dietary consumption of probiotic LAB in a milk-based diet may offer benefit to elderly consumers to combat some of the deleterious effects of immunosenescence on cellular immunity.